Peptilogics Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
21
- Latest Deal Type
-
Later Stage VC
- Investors
-
31
Peptilogics General Information
Description
Developer of a therapeutic and drug discovery peptide platform designed to treat multidrug-resistant bacterial infections. The company's platform offers a new class of antibiotics with a novel mechanism of action derived from their eCAP (engineered cationic antibiotic peptide) that has preclinical effectiveness against resistant bacteria and biofilms, enabling doctors to identify and treat bacterial infections at an affordable cost.
Contact Information
Website
www.peptilogics.comCorporate Office
- 2681 Sidney Street
- Pittsburgh, PA 15203
- United States
Corporate Office
- 2681 Sidney Street
- Pittsburgh, PA 15203
- United States
Peptilogics Timeline
Peptilogics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Later Stage VC | 24-Mar-2026 | Completed | Clinical Trials - General | |||
| 9. Later Stage VC (Series B2) | 16-Oct-2025 | Completed | Clinical Trials - General | |||
| 8. Grant | 11-Jan-2025 | Completed | Clinical Trials - General | |||
| 7. Later Stage VC | 22-May-2025 | Completed | Clinical Trials - General | |||
| 6. Accelerator/Incubator | 02-Aug-2022 | Completed | Clinical Trials - General | |||
| 5. Later Stage VC (Series B) | 30-Dec-2020 | Completed | Clinical Trials - General | |||
| 4. Early Stage VC (Series A) | 29-Sep-2017 | Completed | Startup | |||
| 3. Accelerator/Incubator | 01-Jan-2017 | Completed | Startup | |||
| 2. Seed Round | 21-Oct-2016 | $1.3M | $1.3M | Completed | Startup | |
| 1. University Spin-Out | 01-Jan-2013 | Completed | Startup |
Peptilogics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B3 | ||||||||
| Series B2 | ||||||||
| Series B1 | ||||||||
| Series B | ||||||||
| Series A2 | ||||||||
| Series A1 | 4,788,775 | $0.000100 | $0.02 | $0.31 | $0.31 | 1x | $0.31 | 2.65% |
| Seed | 6,968,639 | $0.000100 | $0.01 | $0.2 | $0.2 | 1x | $0.2 | 3.86% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Peptilogics Comparisons
Industry
Financing
Details
Peptilogics Competitors (18)
One of Peptilogics’s 18 competitors is Gesynta Pharma, a Venture Capital-Backed company based in Stockholm, Sweden.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Gesynta Pharma | Venture Capital-Backed | Stockholm, Sweden | ||||
| AbCellera Biologics | Formerly VC-backed | Vancouver, Canada | ||||
| Numerion Labs | Venture Capital-Backed | San Francisco, CA | ||||
| Cardurion | Venture Capital-Backed | Burlington, MA | ||||
| Relay Therapeutics | Formerly VC-backed | Cambridge, MA |
Peptilogics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Peptilogics Patents
Peptilogics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2023200866-A1 | Computer representations of peptides for efficient design of drug candidates | Inactive | 13-Apr-2022 | ||
| AU-2022345264-A1 | Engineered antimicrobial peptides and usage thereof | Pending | 17-Sep-2021 | ||
| AU-2022346034-A1 | Engineered antimicrobial peptides and usage thereof | Pending | 17-Sep-2021 | ||
| CA-3231957-A1 | Engineered antimicrobial peptides and usage thereof | Pending | 17-Sep-2021 | ||
| CA-3231958-A1 | Engineered antimicrobial peptides and usage thereof | Pending | 17-Sep-2021 | A61K38/162 |
Peptilogics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Peptilogics Investors (31)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Mana Ventures | Venture Capital | Minority | ||
| AMR Action Fund | Impact Investing | Minority | ||
| Beyond Ventures | Venture Capital | Minority | ||
| Thiel Bio | Venture Capital | Minority | ||
| Gaingels | Venture Capital | Minority |
Peptilogics FAQs
-
When was Peptilogics founded?
Peptilogics was founded in 2013.
-
Where is Peptilogics headquartered?
Peptilogics is headquartered in Pittsburgh, PA.
-
What is the size of Peptilogics?
Peptilogics has 21 total employees.
-
What industry is Peptilogics in?
Peptilogics’s primary industry is Drug Discovery.
-
Is Peptilogics a private or public company?
Peptilogics is a Private company.
-
What is Peptilogics’s current revenue?
The current revenue for Peptilogics is .
-
How much funding has Peptilogics raised over time?
Peptilogics has raised $195M.
-
Who are Peptilogics’s investors?
Mana Ventures, AMR Action Fund, Beyond Ventures, Thiel Bio, and Gaingels are 5 of 31 investors who have invested in Peptilogics.
-
Who are Peptilogics’s competitors?
Gesynta Pharma, AbCellera Biologics, Numerion Labs, Cardurion, and Relay Therapeutics are some of the 18 competitors of Peptilogics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
